We hypothesize that inhibition of PI3K is the common mechanism involved in the anti-CRC effect of both MET, ASP, and their combination and that, therefore, the combination of MET + ASP will probably benefit PI3KCA-mutant CRC cases, which have currently a poor prognostic (as already observed in relation to ASP only; see above). This evidence concerns the gene MET and colorectal carcinoma.